Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - CymaBay Therapeutics, Inc. | cbay-ex321_6.htm |
| EX-31.2 - EX-31.2 - CymaBay Therapeutics, Inc. | cbay-ex312_7.htm |
| EX-31.1 - EX-31.1 - CymaBay Therapeutics, Inc. | cbay-ex311_8.htm |
| EX-10.20 - EX-10.20 - CymaBay Therapeutics, Inc. | cbay-ex1020_170.htm |
| EX-10.19 - EX-10.19 - CymaBay Therapeutics, Inc. | cbay-ex1019_168.htm |
| EX-10.7 - EX-10.7 - CymaBay Therapeutics, Inc. | cbay-ex107_169.htm |
| 10-K - 10-K - CymaBay Therapeutics, Inc. | cbay-10k_20171231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statements (Form S-3 Nos. 333-222372 and 333-192617) of CymaBay Therapeutics, Inc., and |
|
|
(2) |
Registration Statements (Form S-8 Nos. 333-195211, 333-198289, 333-202941, 333-210453, and 333-216905) pertaining to the Metabolex, Inc. 2003 Equity Incentive Plan, and the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan, |
of our report dated March 15, 2018, with respect to the financial statements of CymaBay Therapeutics, Inc., included in this Annual Report (Form 10-K) of CymaBay Therapeutics, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Redwood City, California
March 15, 2018